Antihypertensive Drugs in Pregnancy

Seminars in Nephrology

Volumn 31, Issue 1, 2011, Pages 70-85

  Podymow, Tiina ^a   August, Phyllis ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antihypertensive drugs; Hypertension; Lactation; Postpartum; Pregnancy

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DIAZOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; ISOSORBIDE DINITRATE; ISRADIPINE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PRAZOSIN; RENIN INHIBITOR; SEROTONIN 2 ANTAGONIST; SPIRONOLACTONE; TRIAMTERENE; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; BREAST FEEDING; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ECLAMPSIA; ELECTROLYTE DISTURBANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOXIA; KIDNEY FAILURE; LABOR INHIBITION; LACTATION; MATERNAL HYPERTENSION; NEUROMUSCULAR BLOCKING; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RISK ASSESSMENT; SHOCK; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY; SEVERITY OF ILLNESS INDEX;

EID: 78751691257     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.10.007     Document Type: Article

References (113)

1. High blood pressure in pregnancy. Am J Obstet Gynecol 2000, 183:S1-S22. Report of the National High Blood Pressure Education Program Working Group.
2. Samadi A.R., Mayberry R.M., Zaidi A.A., Pleasant J.C., McGhee N., Rice R.J. Maternal hypertension and associated pregnancy complications among African-American and other women in the United States. Obstet Gynecol 1996, 87:557-563.
3. Sibai B.M. Antihypertensive drugs during pregnancy. Semin Perinatol 2001, 25:159-164.
4. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
5. Abalos E., Duley L., Steyn D., Henderson-Smart D. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007, 1. CD002252.
6. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
7. Levine R.J., Thadhani R., Qian C., et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005, 293:77-85.
8. Moodley J. Maternal deaths due to hypertensive disorders in pregnancy. Best Pract Res Clin Obstet Gynaecol 2008, 22:559-567.
9. Sibai B.M. Chronic hypertension in pregnancy. Obstet Gynecol 2002, 100:369-377.
10. Davis G.K., Mackenzie C., Brown M.A., et al. Predicting transformation from gestational hypertension to preeclampsia in clinical practice: a possible role for 24 hour ambulatory blood pressure monitoring. Hypertens Pregnancy 2007, 26:77-87.
11. Barton J.R., O'Brien J.M., Bergauer N.K., Jacques D.L., Sibai B.M. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol 2001, 184:979-983.
12. Brown M.A., Buddle M.L. Hypertension in pregnancy: maternal and fetal outcomes according to laboratory and clinical features. Med J Aust 1996, 165:360-365.
13. von Dadelszen P., Magee L.A. Antihypertensive medications in management of gestational hypertension-preeclampsia. Clin Obstet Gynecol 2005, 48:441-459.
14. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2001, 1. CD002252.
15. Magee L.A., Ornstein M.P., von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ 1999, 318:1332-1336.
16. von Dadelszen P., Ornstein M.P., Bull S.B., Logan A.G., Koren G., Magee L.A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000, 355:87-92.
17. Helewa M.E., Burrows R.F., Smith J., Williams K., Brain P., Rabkin S.W. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997, 157:715-725.
18. Magee L.A. Diagnosis, evaluation, and management of thehypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008, 30(Suppl 1):S1.
19. Brown M.A., Hague W.M., Higgins J., et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol 2000, 40:139-155.
20. Martin J.N., Thigpen B.D., Moore R.C., Rose C.H., Cushman J., May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005, 105:246-254.
21. Sibai B.M., Barton J.R. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 2007, 196:514.e1-514.e9.
22. Withagen M.I., Wallenburg H.C., Steegers E.A., Hop W.C., Visser W. Morbidity and development in childhood of infants born after temporising treatment of early onset pre-eclampsia. BJOG 2005, 112:910-914.
23. Magee L.A. Drugs in pregnancy. Antihypertensives. Best Pract Res Clin Obstet Gynaecol 2001, 15:827-845.
24. Rey E., LeLorier J., Burgess E., Lange I.R., Leduc L. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ 1997, 157:1245-1254.
25. Duley L., Henderson-Smart D.J., Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006, 3. CD001449.
26. Magee L.A., Cham C., Waterman E.J., Ohlsson A., von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003, 327:955-960.
27. Lindheimer M.D., Grunfeld J.-P., Davison J.M. Medical Disorders During Pregnancy 2000, Mosby Inc, St Louis, MO. (ed 3).
28. Teratology Society Public Affairs Committee. Teratology 1994, 49:446-447. FDA classification of drugs for teratogenic risk.
29. Umans J.G. Medications during pregnancy: antihypertensives and immunosuppressives. Adv Chronic Kidney Dis 2007, 14:191-198.
30. Redman C.W. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 1976, 2:753-756.
31. Sibai B.M., Mabie W.C., Shamsa F., Villar M.A., Anderson G.D. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990, 162:960-967.
32. Leather H.M., Humphreys D.M., Baker P., Chadd M.A. A controlled trial of hypotensive agents in hypertension in pregnancy. Lancet 1968, 2:488-490.
33. Fidler J., Smith V., Fayers P., De Swiet M. Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br Med J (Clin Res Ed) 1983, 286:1927-1930.
34. Gallery E.D., Ross M.R., Gyory A.Z. Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. Br Med J (Clin Res Ed) 1985, 291:563-566.
35. Plouin P.F., Breart G., Maillard F., Papiernik E., Relier J.P. Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. Br J Obstet Gynaecol 1988, 95:868-876.
36. Redman C.W., Beilin L.J., Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynaecol 1977, 84:419-426.
37. Montan S., Anandakumar C., Arulkumaran S., Ingemarsson I., Ratnam S.S. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol 1993, 168:152-156.
38. Mutch L.M., Moar V.A., Ounsted M.K., Redman C.W. Hypertension during pregnancy, with and without specific hypotensive treatment. I. Perinatal factors and neonatal morbidity. Early Hum Dev 1977, 1:47-57.
39. Mutch L.M., Moar V.A., Ounsted M.K., Redman C.W. Hypertension during pregnancy, with and without specific hypotensive treatment. II. The growth and development of the infant in the first year of life. Early Hum Dev 1977, 1:59-67.
40. Cockburn J., Moar V.A., Ounsted M., Redman C.W. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982, 1:647-649.
41. Schweitzer I.L., Peters R.L. Acute submassive hepatic necrosis due to methyldopa. A case demonstrating possible initiation of chronic liver disease. Gastroenterology 1974, 66:1203-1211.
42. Horvath J.S., Phippard A., Korda A., Henderson-Smart D.J., Child A., Tiller D.J. Clonidine hydrochloride-a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol 1985, 66:634-638.
43. Huisjes H.J., Hadders-Algra M., Touwen B.C. Is clonidine a behavioural teratogen in the human? Early Hum Dev 1986, 14:43-48.
44. Rubin P.C., Butters L., Clark D.M., et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 1983, 1:431-434.
45. Paran E., Holzberg G., Mazor M., Zmora E., Insler V. Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. Int J Clin Pharmacol Ther 1995, 33:119-123.
46. Magee L.A., Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2000, 4. CD002863.
47. Butters L., Kennedy S., Rubin P.C. Atenolol in essential hypertension during pregnancy. BMJ 1990, 301:587-589.
48. Lip G.Y., Beevers M., Churchill D., Shaffer L.M., Beevers D.G. Effect of atenolol on birth weight. Am J Cardiol 1997, 79:1436-1438.
49. Magee L.A., Elran E., Bull S.B., Logan A., Koren G. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 2000, 88:15-26.
50. Waterman E.J., Magee L.A., Lim K.I., Skoll A., Rurak D., von Dadelszen P. Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypertens Pregnancy 2004, 23:155-169.
51. Reynolds B., Butters L., Evans J., Adams T., Rubin P.C. First year of life after the use of atenolol in pregnancy associated hypertension. Arch Dis Child 1984, 59:1061-1063.
52. Pickles C.J., Symonds E.M., Pipkin F.B. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol 1989, 96:38-43.
53. Sibai B.M., Gonzalez A.R., Mabie W.C., Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 1987, 70:323-327.
54. Munshi U.K., Deorari A.K., Paul V.K., Singh M. Effects of maternal labetalol on the newborn infant. Indian Pediatr 1992, 29:1507-1512.
55. Freier D.T., Thompson N.W. Pheochromocytoma and pregnancy: the epitome of high risk. Surgery 1993, 114:1148-1152.
56. Grodski S., Jung C., Kertes P., Davies M., Banting S. Phaeochromocytoma in pregnancy. Intern Med J 2006, 36:604-606.
57. Magee L.A., Schick B., Donnenfeld A.E., et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996, 174:823-828.
58. Bartels P.A., Hanff L.M., Mathot R.A., Steegers E.A., Vulto A.G., Visser W. Nicardipine in pre-eclamptic patients: placental transfer and disposition in breast milk. BJOG 2007, 114:230-233.
59. Jannet D., Carbonne B., Sebban E., Milliez J. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. Obstet Gynecol 1994, 84:354-359.
60. Wide-Swensson D.H., Ingemarsson I., Lunell N.O., et al. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. Am J Obstet Gynecol 1995, 173:872-878.
61. Casele H.L., Windley K.C., Prieto J.A., Gratton R., Laifer S.A. Felodipine use in pregnancy. Report of three cases. J Reprod Med 1997, 42:378-381.
62. Belfort M.A., Anthony J., Buccimazza A., Davey D.A. Hemodynamic changes associated with intravenous infusion of the calcium antagonist verapamil in the treatment of severe gestational proteinuric hypertension. Obstet Gynecol 1990, 75:970-974.
63. Ahn H.K., Nava-Ocampo A.A., Han J.Y., et al. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertens Pregnancy 2007, 26:179-187.
64. Papatsonis D.N., Lok C.A., Bos J.M., Geijn H.P., Dekker G.A. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol 2001, 97:122-140.
65. Lindow S.W., Davies N., Davey D.A., Smith J.A. The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. Br J Obstet Gynaecol 1988, 95:1276-1281.
66. Rizzo G., Arduini D., Mancuso S., Romanini C. Effects of nifedipine on umbilical artery velocity waveforms in healthy human fetuses. Gynecol Obstet Invest 1987, 24:151-154.
67. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326-1331.
68. Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993, 100:959-961.
69. Puzey M.S., Ackovic K.L., Lindow S.W., Gonin R. The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancies complicated by hypertension. S Afr Med J 1991, 79:192-194.
70. Brown M.A., Buddle M.L., Farrell T., Davis G.K. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 2002, 187:1046-1050.
71. Ales K. Magnesium plus nifedipine. Am J Obstet Gynecol 1990, 162:288.
72. Waisman G.D., Mayorga L.M., Camera M.I., Vignolo C.A., Martinotti A. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol 1988, 159:308-309.
73. Ben-Ami M., Giladi Y., Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol 1994, 101:262-263.
74. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359:1877-1890.
75. Scardo J.A., Vermillion S.T., Hogg B.B., Newman R.B. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1996, 175:336-340.
76. Magee L.A., Miremadi S., Li J., et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005, 193:153-163.
77. Collins R., Yusuf S., Peto R. Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) 1985, 290:17-23.
78. Groves T.D., Corenblum B. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol 1995, 172:1655-1656.
79. Bolte A.C., van Geijn H.P., Dekker G.A. Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers. Eur J Obstet Gynecol Reprod Biol 2001, 95:22-36.
80. Steyn D.W., Odendaal H.J. Serotonin antagonism and serotonin antagonists in pregnancy: role of ketanserin. Obstet Gynecol Surv 2000, 55:582-589.
81. Widerlov E., Karlman I., Storsater J. Hydralazine-induced neonatal thrombocytopenia. N Engl J Med 1980, 303:1235.
82. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003, 24:761-781.
83. Mabie W.C., Gonzalez A.R., Sibai B.M., Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 1987, 70:328-333.
84. Fenakel K., Fenakel G., Appelman Z., Lurie S., Katz Z., Shoham Z. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991, 77:331-337.
85. Vink G.J., Moodley J., Philpott R.H. Effect of dihydralazine on the fetus in the treatment of maternal hypertension. Obstet Gynecol 1980, 55:519-522.
86. Nevo O., Thaler I., Shik V., Vortman T., Soustiel J.F. The effect of isosorbide dinitrate, a donor of nitric oxide, on maternal cerebral blood flow in gestational hypertension and preeclampsia. Am J Obstet Gynecol 2003, 188:1360-1365.
87. Shoemaker C.T., Meyers M. Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity. Am J Obstet Gynecol 1984, 149:171-173.
88. Wasserstrum N. Nitroprusside in preeclampsia. Circulatory distress and paradoxical bradycardia. Hypertension 1991, 18:79-84.
89. Sass N., Itamoto C.H., Silva M.P., Torloni M.R., Atallah A.N. Does sodium nitroprusside kill babies? A systematic review. Sao Paulo Med J 2007, 125:108-111.
90. Pryde P.G., Sedman A.B., Nugent C.E., Barr M. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 1993, 3:1575-1582.
91. Buttar H.S. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development. Mol Cell Biochem 1997, 176:61-71.
92. Briggs G.G., Nageotte M.P. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 2001, 35:859-861.
93. Lambot M.A., Vermeylen D., Noel J.C. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001, 357:1619-1620.
94. Saji H., Yamanaka M., Hagiwara A., Ijiri R. Losartan and fetal toxic effects. Lancet 2001, 357:363.
95. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006, 354:2443-2451.
96. Lennestal R., Otterblad Olausson P., Kallen B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009, 65:615-625.
97. Walters B.N., Thompson M.E., Lee A., de Swiet M. Blood pressure in the puerperium. Clin Sci (Lond) 1986, 71:589-594.
98. Magee L., Sadeghi S. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev 2005, 1. CD004351.
99. Tan L.K., de Swiet M. The management of postpartum hypertension. BJOG 2002, 109:733-736.
100. Podymow T., August P. Postpartum course of gestational hypertension and preeclampsia. Hypertens Pregnancy 2010, 29:294-300.
101. Beardmore K.S., Morris J.M., Gallery E.D. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy 2002, 21:85-95.
102. Ascarelli M.H., Johnson V., McCreary H., Cushman J., May W.L., Martin J.N. Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstet Gynecol 2005, 105:29-33.
103. Makris A., Thornton C., Hennessy A. Postpartum hypertension and nonsteroidal analgesia. Am J Obstet Gynecol 2004, 190:577-578.
104. Atkinson H.C., Begg E.J., Darlow B.A. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988, 14:217-240.
105. Breitzka R.L., Sandritter T.L., Hatzopoulos F.K. Principles of drug transfer into breast milk and drug disposition in the nursing infant. J Hum Lact 1997, 13:155-158.
106. Ilett K.F., Kristensen J.H. Drug use and breastfeeding. Expert Opin Drug Saf 2005, 4:745-768.
107. Atkinson H., Begg E.J. Concentrations of beta-blocking drugs in human milk. J Pediatr 1990, 116:156.
108. White W.B. Management of hypertension during lactation. Hypertension 1984, 6:297-300.
109. Ehrenkranz R.A., Ackerman B.A., Hulse J.D. Nifedipine transfer into human milk. J Pediatr 1989, 114:478-480.
110. Shannon M.E., Malecha S.E., Cha A.J. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and lactation: an update. J Hum Lact 2000, 16:152-155.
111. Transfer of drugs and other chemicals into human milk. Pediatrics 2001, 108:776-789.
112. Magee L.A., Bull S.B., Koren G., Logan A. The generalizability of trial data; a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy. Eur J Obstet Gynecol Reprod Biol 2001, 94:205-210.
113. Podymow T., August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008, 51:960-969.